1. Home
  2. CCO vs XERS Comparison

CCO vs XERS Comparison

Compare CCO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clear Channel Outdoor Holdings Inc.

CCO

Clear Channel Outdoor Holdings Inc.

HOLD

Current Price

$2.33

Market Cap

1.2B

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$8.51

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCO
XERS
Founded
1995
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.5B
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
CCO
XERS
Price
$2.33
$8.51
Analyst Decision
Hold
Buy
Analyst Count
5
6
Target Price
$2.12
$10.83
AVG Volume (30 Days)
7.3M
1.6M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
110.81
100.00
EPS
N/A
N/A
Revenue
$1,604,140,000.00
$49,590,000.00
Revenue This Year
$5.35
$34.37
Revenue Next Year
$4.26
$22.86
P/E Ratio
N/A
N/A
Revenue Growth
6.57
142.67
52 Week Low
$1.16
$5.25
52 Week High
$2.44
$10.08

Technical Indicators

Market Signals
Indicator
CCO
XERS
Relative Strength Index (RSI) 32.05 57.24
Support Level $2.33 $6.98
Resistance Level $2.41 $9.01
Average True Range (ATR) 0.03 0.34
MACD -0.01 -0.00
Stochastic Oscillator 25.00 89.64

Price Performance

Historical Comparison
CCO
XERS

About CCO Clear Channel Outdoor Holdings Inc.

Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: